An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy

The study investigates the combination of copper-doped mesoporous silica nanoparticles (MS-Cu) and disulfiram (DSF) for chemoimmunotherapy, showing significant tumor inhibition in vitro and in vivo. MS-Cu–2 nanoparticles (200 nm) demonstrated superior tumor microenvironment modulation and strong cell-killing effects at low doses (1–10 μg/mL). In vivo experiments on 20 Lewis lung carcinoma (LLC) tumor-bearing mice revealed that DSF/MS-Cu–2 combined with an anti-CTLA-4 antibody significantly reduced tumor size and weight compared to individual treatments, indicating a promising synergistic antitumor effect. Further research on Cu metabolism and detailed mechanisms is needed for clinical applications.